On January 15, Jemincare Group, a Chinese pharmaceutical company, announced 
that it has initiated the phase I clinical trial of anti-SARS-CoV-2 
neutralizing antibody (JMB2002).

Preclinical studies of JMB2002 including pharmacology and toxicity were carried 
out systemically. The drug metabolism, safety and efficacy were well performed. 
In early studies, it was found that JMB2002 could effectively neutralize live 
virus infection of Vero E6 cells. What's more, JMB2002 showed potent binding 
and blocking activities to the spike glycoproteins of mutant viruses. 

While most of the SARS-CoV-2 neutralizing antibodies in clinical trial are 
produced from cell pool, the product for clinical trial of JMB2002 is produced 
from high yield stable cell line, that ensure the consistency and stability of 
clinical samples. JMB2002 is derived from naive human B cell antibody library 
of healthy donors. With the powerful phage-to-yeast platform, researchers 
quickly pinpoint the ideal candidates from over 10 billion antibody molecules 
in 19 days.

As one of the large-scale and modernized pharmaceutical groups in China, 
Jemincare Group, making breakthrough achievements in recent 2 years, has 
focused on the R&D of new drugs over the years with R&D pipeline for treating 
diseases in cancer, central nervous system, respiratory system, cardiovascular 
and cerebrovascular systems. In 2018, Jemincare established its Research 
Institute in Shanghai Zhangjiang Science City and has recruited over 400 R&D 
scientists in 5 research centers for development of innovative drugs including 
biologics, novel small molecules, novel drug delivery system, generic drugs and 
traditional Chinese medicines.

For more information, please visit 
http://www.jemincare.com/ , 
https://mp.weixin.qq.com/s/ctxPE6bA2CIvfknZoRwwKg

Source: Jemincare